See referenced original article on pages 258-67, this issue.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Editorial
You have full text access to this OnlineOpen article
What is the best way to treat high-risk prostate cancer?†
Article first published online: 30 JUN 2011
DOI: 10.1002/cncr.26281
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Klein, E. A. (2012), What is the best way to treat high-risk prostate cancer?. Cancer, 118: 12–14. doi: 10.1002/cncr.26281
- †
Publication History
- Issue published online: 16 DEC 2011
- Article first published online: 30 JUN 2011
- Manuscript Accepted: 9 MAY 2011
- Manuscript Received: 5 MAY 2011
REFERENCES
- 1, . Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: A decision analysis. Cancer. 2011; 118:258-267.
- 2, , , et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
- 3, , , et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007; 99: 1171-1177.
- 4, , , et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
- 5, , , et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
- 6
- 7, , . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4456.
- 8, , , et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010; 121: 833-840.
- 9, , , , . Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005; 95: 751-756.
- 10, , , , . Radical prostatectomy for clinical stage T3a disease. Cancer. 2007; 109: 1273-1278.
- 11, , , et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. [published online ahead of print January 10, 2011.]
- 12, , , , , . What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010; 76: 710-714.
- 13, , , et al. Avoiding androgen deprivation therapy in men with high risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology. 2011; 77: 946-950.
- 14, , , et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010; 28: 1508-1513.
- 15, , , . Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116: 5226-5234.
- 16, , , et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185: 869-875.